维普期刊资源整合服务平台（V6.5）

27篇 您的检索式：作者名="Moulder SL"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Phase Ⅰ/Ⅱ study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer 显示文摘	Moulder SL Symmans WF Booser DJ	2008	Clin Cancer Res2008，14，23：	1
2	Epidermal growth factor receptor ( HER1 ) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo 显示文摘	Moulder SL Yakes FM Muthuswamy SK	2001	Cancer Res2001，61，：	1
3	Does the PI3K pathway play a role in basal breast cancer?显示文摘	Moulder SL	2010	Clin Breast Cancer2010，103，：	1
4	Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo显示文摘	Moulder SL Yakes FM Muthuswamy SK		0，，：	1
5	HER(erbB)tyrosine kinase inhibitors in the treatment fo breast cancer显示文摘	Arteaga CL Moulder SL yakes FM	2002	Semin Oncol2002，29，11：	1
6	Sulfated glycans stimulate endocytosis of the cellular isoform of the prion protein,PrPC,in cultured cells显示文摘	Shyng SL Lehmann S Moulder KL	1995	J Biol Chem1995，270，30：	1
7	Anastrozole and everolimus in advanced gynecologic and breast malignancies:activity and molecular alterations in the PI3K/AKT/mTOR pathway显示文摘	Wheler JJ Moulder SL Naing A		Oncotarget0，5，10：	1
8	HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer显示文摘	Arteaga CL Moulder SL Yakes FM	2002	Semin Oncol2002，29，311：	1
9	Phase Ⅰ / Ⅱ study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer显示文摘	Moulder SL Symmans WF Booser DJ	2008	Clin Can- cer Res2008，14，23：	1
10	ECOGll00: a phase Ⅰ-Ⅱ study of combined blockade of the erbB receptor network with trastuzmab and gefitinib ( ‘lressa' ) in patients (pts) with HER-2-overexpressing metastatic breast cancer显示文摘	Arteaga CL O'Neil A Moulder SL	2004	Breast Cancer Res Treat2004，88，1：	1
11	HER-2(c-erbB-2) tyrosine kinase inhibitors in the treatment of breast cancer显示文摘	Arteaga CI Moulder SL Yakes FM	2002	Serain Oncol2002，29，11：	1
12	Dual HER2inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer显示文摘	Falchook GS Moulder SL Wheler JJ	2013	Ann Oncol2013，24，12：	1
13	HER (erbB) Tyrosine kinase Inhibitor's in the treatment of breast cancer 显示文摘	Arteaga C Moulder SL Yakes MY	2002	Semin Oncol2002，29，11：	1
14	HER(erbB) tyrosine kinase inhibitors in the treatment of breast cancer显示文摘	Arteaga C Moulder SL Yakes MY	2002	Semin Oncol2002，29，11：	1
15	HER tyosine kinase inhibitors in the treatment of breast cancer显示文摘	Arteaga CL Moulder SL Yakes FM		0，，11：	1
16	HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer显示文摘	Arteaga CL Moulder SL Yakes FM	2002	Semin Oncol2002，29，11：	1
17	Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer 显示文摘	Falchook GS Moulder SL Wheler JJ	2013	Ann Oncol2013，24，12：	1
18	HER (erb)B) tyrosine kinase inhibitors in the treatment of breasl cancer显示文摘	Arteaga CL Moulder SL Yakes FM	2002	Semin Oncol2002，29，11：	1
19	Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer显示文摘	Esteva FJ Moulder SL Gonzalez-Angulo AM	2013	Cancer Chemother Pharmacol2013，71，1：	1
20	Epidermal growth factor receptor (HERl)tyrosine kinase inhibitor ZD1839 (Iressa)inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo显示文摘	Moulder SL Yakes FM Muthuswamy SK	2001	Cancer Res2001，61，24：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示